Dino Prato presents a case study of Fran, a patient with metastatic lung cancer and brain metastases who achieved complete remission without conventional chemotherapy. The approach combined deep molecular mapping, customized immunotherapies including NK and dendritic cell treatments, metronomic chemotherapy, repurposed drugs, and gut microbiome work, monitored through liquid biopsy.
Fran was diagnosed with metastatic non small cell lung cancer with brain metastases. Her symptoms were dizziness, weakness, low energy, memory loss, constant coughing. And when offered conventional chemo and palliative radiation. At that point she said no more chemotherapy. Most doctors would have stopped right there, but we didn't. Because no chemo doesn't have to mean no hope. We use precision oncology, a blueprint that used genetically targeted fractionated chemotherapy. After we did deep mapping and we got her immune system involved with a toggless ADOP immunotherapy that was matched to her dams damage associated molecular patterns. Lung cancer works so well for immunotherapy. In fact, one of the common treatments is PD1 inhibitors. But it doesn't always work long term. And the secret to this is you need good immune spatial biology and mapping of the RNA transcriptomics and DNA next generation sequencing to find the right immunotherapy targets. And then on label, off label repurposed drugs, phytotherapeutic nanoparticles with building the natural killer cells and dendritic cells to help the immune helped her reach complete resolution. She got systemic care. In fact, as soon as she got her cells back, her natural killer cells and dendritic cells that were typed to her damps and peptides, the cancer really improved and cleared. She refused chemo, but then her tumors disappeared because of immunotherapy. And that's the power of precision oncology. So I just want to say this because there's a lot of lung cancers out there that often will do immunotherapy and exhaust it. But remember that you can custom develop the immunotherapy to turn those cold tumors hot and get custom care for them when you know what the targets are. So here the first part, you need deep mapping. If you're only running DNA, that's not enough. You need transcriptomics and immune spatial biology. This is over a thousand plus data points versus let's say of several hundred that you might have with DNA. Then you have to match the therapies and custom build them in the pharmacy just for the patient. And the design has to be all immune centric. You want immunogenic cell death, you want to get the immune system to kill the cancer. Because particularly with lung cancer, that is so important. That's what my team and I have been doing for the last 25 years. We've been helping patients who have cancer treatment in the top hospitals. And when working with cancers like lung cancer, it is an immunogenic cancer very much responsive to the immune system. But you have to have the right targets in the standard of care path. Fran would have had to done more chemotherapy and radiation for palliative care, but it already had spread to the brain. And the treatment that she had done didn't work. So she needed better planning. She didn't want the one size fits all. I talk about this all the time because in oncology, you have what's called step therapy. You start something, fail it, Then you go to the next step, the next regimen, but it's not typed on you. Yeah, you be given a smart drug that slows things down. But you might want to watch one of my other episodes on this, on how most of these smart drugs are cytostatic. They slow cancer down. They're not cytotoxic. They don't kill cancer. We want to go from managing cancer to eliminating that. And the way we do that is through immunity. She didn't want to do palliative care because this is how it works. Go to the tumor board or refer over to radiation oncology, and the discussion becomes radiation palliative care to the brain or to the bone or wherever the mets are. But this isn't the key in deep mapping. We want to go to the cause of the cancer, get the immune system turned on. Then we let the immune system do what it does best. Go after the cancer. These cells, like natural killer cells, they don't need a special ID badge. They can get right to where they need to go. They can burrow through the tissue to the bones, get to the brain. And for this patient, that's what works so well. Because we had the mapping, we were able to custom build the program just for her. And it's simple because even when we monitor the patient, we use blood tests. We draw blood from the arm, like we call it liquid biopsy, so we can see cells that may have left a tumor Called circulating tumor cells, CT methylation scores that shows us that the cancer is holding remission or that it's trying to come back. And then we can still do the genetic targeting to go after on label, off label, repurposed drugs. This is the important thing, because when you're dealing with cancers that have passed a blood brain barrier, we need an ability to do treatment. And so how do we do that? We do that using the immune system and other techniques with genetically targeted fractionated chemotherapy, what's called metronomic dose chemotherapy, that can get to the brain and get to the tissue so we can get the effects that we need without all the side effects because we're using microdosing that is specific from testing. So this is why it's so important to have all these data points. Because who wants to be treated with less data? Who wants to be treated with a few data points and a basic DNA NGS test and using an inhibitor that slows things down, that's fine. But long term you want a thousand plus data points and you want a playbook that is going to go after the cancer using the immune system. So even when you shut off the cancer, metabolically remove the sugar, the refined carbohydrates, that's all helpful. But ultimately you need the immune system to do the work. Especially in these types of cancers where late stage, they're refractory to care and they need this type of targeting. That's the power of precision oncology. So instead of wiping the immune system out with high dose chemo or using radiation for palliative care, using a toggless adaptive immunotherapy with natural killer cells, dendritic cells type to her damps molecules. These damage associated molecular patterns, these danger signals that turn the immune system on and teach it to go after tumors with the natural killer cells and dendritic cells. That's what helped her go into remission. For her, this was the right target. Fran got the care she needed. It was an immunogenic cel immune system was able to kill the cancer. We were able to use on label, off label and repurposed drugs to target care phytotherapeutics that augmented the treatment. So now one plus one equals 11 and we're going after the cancer. Of course we did all the dietary fix the gut microbiome, get rid of the refined carbohydrates, shut down the metabolic feeders to cancer. But we were able to target it through the immune system because that's how we see the best chance for durable remissions with patients. So precision isn't only a lab work. It isn't, you know, just guessing. It's alignment of everything from the pharmacy to the delivery of care, along with the testing that gives you the exact targets of what you need. This is how we restore health to the patient and we give them the opportunity to get the response to care that they weren't able to do before. I hope this was helpful in sharing this story. And may the Lord bless you on your journey to healing. Sa.
